EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase).
Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
Belzutifan (PT2977) is a second-generation orally active and selective HIF-2α inhibitor with an IC50 of 9 nM.
Belzutifan (PT2977) is a second-generation orally active and selective HIF-2α inhibitor with an IC50 of 9 nM.
PF-06700841 is a first-in-class oral dual inhibitor of JAK1 and TYK2 with IC50 values of 17 nM and 23 nM, respectively.PF-06700841 also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively.
PF-06700841 is a first-in-class oral dual inhibitor of JAK1 and TYK2 with IC50 values of 17 nM and 23 nM, respectively.PF-06700841 also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively.
Pirtobrutinib (LOXO-305; LY 3527727; RXC-005) is a first-in-class, highly selective, non-covalent, next-generation BTK inhibitor with an IC50 of 5.69 nM in WT BTK HEK cells.Pirtobrutinib's selectivity for BTK more than 300 times more selective than other 370 kinases. Pirtobrutinib can be used in studies related to chronic lymphocytic leukemia (CLL).
Pirtobrutinib (LOXO-305; LY 3527727; RXC-005) is a first-in-class, highly selective, non-covalent, next-generation BTK inhibitor with an IC50 of 5.69 nM in WT BTK HEK cells.Pirtobrutinib's selectivity for BTK more than 300 times more selective than other 370 kinases. Pirtobrutinib can be used in studies related to chronic lymphocytic leukemia (CLL).
H3B-8800 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1). H3B-8800 binds SF3B1 and exhibits significant antitumor activity by eliminating disruption of mRNA splicing.